Biopharma & Oncology: Immunology Cash Machine vs Oncology Pipeline
ABBV vs BMY: Head-to-Head Comparison
Comparing quantitative economic moats, Forward P/E multiples, balance sheet liquidity, and institutional 13F whale conviction.
VS
👑 Higher Moat Score
BMY
BMY 🇺🇸
Bristol-Myers Squibb Company
$45.00
+0.00%
MOAT SCORE
⚡ 84.0/100
📊 Quantitative Fundamental Matchup
| Fundamental Metric | ABBV (AbbVie Inc.) | BMY (Bristol-Myers Squibb Company) | Advantage |
|---|---|---|---|
| Moat Score™ (0-100) | ⚡ 74.0 | ⚡ 84.0 | BMY (+10.0 pts) |
| Market Capitalization | $454.4B | $8.5B | - |
| Forward P/E Ratio | 18.4x | 18.5x | ABBV (Cheaper Multiple) |
| Trailing P/E Ratio | 72.4x | 21.0x | - |
| Gross Profit Margin | 72.8% | 44.0% | ABBV (Higher Pricing Power) |
| YoY Revenue Growth | +10.2% | +9.2% | ABBV |
| Free Cash Flow | $16.9B | $420M | - |
| Superinvestor 13F Backing | None Tracked | None Tracked | - |
🏆 The MoatPicks Verdict: BMY Wins on Fundamentals
Based on our 12-point quantitative audit, BMY (Bristol-Myers Squibb Company) achieves an overall Moat Score of 84.0/100 compared to 74.0/100 for ABBV. BMY demonstrates superior capital allocation efficiency, wider gross margins, and stronger defensive economic moat characteristics in the Biopharma & Oncology sector.
Find All 100+ Top-Ranked Moat Compounders
Get real-time 3-hour price updates, 13F whale transaction alerts, and complete 12-point fundamental breakdowns.
Unlock MoatPicks PRO →